Screener
Sarepta Therapeutics, Inc. SRPT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Other current liabilities | 16,562 | 11,393 |
| Total current liabilities | 502,908 | 1,095,290 |
| Long-term debt | 847,623 | 828,974 |
| Lease liabilities, net of current portion | 198,226 | 199,378 |
| Deferred revenue, net of current portion | 110,132 | 83,910 |
| Other non-current liabilities | 1,825 | 1,529 |
| Total liabilities | 1,660,714 | 2,209,081 |
| Commitments and contingencies (Note 16) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s operating lease liabilities?
- Sarepta Therapeutics, Inc. (SRPT) reported operating lease liabilities of $198.23M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Sarepta Therapeutics, Inc.'s operating lease liabilities decreased by 7.6% year-over-year, from $214.42M to $198.23M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s operating lease liabilities has grown at a 19.9% compound annual growth rate (CAGR), from $80.37M to $199.38M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Sarepta Therapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude